LOCALLY ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for LOCALLY ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a common heart drug boost cancer treatment?
Disease control Recruiting nowThis study tests whether adding propranolol (a beta-blocker used for heart conditions) to standard chemotherapy and immunotherapy (pembrolizumab) can improve treatment for advanced esophageal or gastroesophageal junction cancer that cannot be surgically removed. About 40 adults w…
Matched conditions: LOCALLY ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 26, 2026 11:55 UTC
-
New drug duo targets hard-to-treat stomach cancers
Disease control Recruiting nowThis early-stage study tests two drugs together for people with HER2-positive stomach cancer or other solid tumors that have spread or can't be removed. The drugs, trastuzumab deruxtecan and azenosertib, aim to kill cancer cells more effectively. The main goals are to find the be…
Matched conditions: LOCALLY ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:51 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps the immune syst…
Matched conditions: LOCALLY ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug combo hopes to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a combination of two drugs—trifluridine/tipiracil (a chemotherapy) and talazoparib (a targeted therapy)—in people with advanced colorectal or gastroesophageal cancers that have spread. The main goals are to find the safest dose and understand side eff…
Matched conditions: LOCALLY ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 22, 2026 14:03 UTC